Analyze the Regulatory Landscape, Market Competition and Clinical Process to Maximize Commercial Potential
- Washington, District of Columbia
Position Yourself for Commercial Success in the Evolving Biosimilars Landscape
With the FDA releasing new guidelines concerning the development of biosimilars, understanding the regulatory and commercial realities of the biologics market is more important than ever. Join the discussion as your industry peers address this for the very first time as a group at CBI’s 7th Summit on Biosimilars and Follow-On Biologics.
Our summit places unique focus on the assessment of market access, strategies for effective commercialization and options for interchangeability. Explore the current climate for biosimilars business including evaluation of the competitive landscape, reimbursement considerations and patient safety.
This interactive forum covers :
- Understanding the nuances and implications of the FDA guidelines on biosimilars
- Analyzing Europe’s role in biosimilar development
- Determining the appropriate pricing scheme for biosimilars
- Ensuring appropriate nomenclature and labeling of biosimilars
- Comparing the challenges of interchangeable vs. similar biologics
SEE WHO YOU'LL MEET!
